# NM-IL-12 (rHuIL-12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy

> **NCT02544724** · PHASE2 · UNKNOWN · sponsor: **Neumedicines Inc.** · enrollment: 12 (estimated)

## Conditions studied

- Lymphoma, Large B-Cell, Diffuse (DLBCL)

## Interventions

- **BIOLOGICAL:** NM-IL-12

## Key facts

- **NCT ID:** NCT02544724
- **Lead sponsor:** Neumedicines Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-11
- **Primary completion:** 2017-08
- **Final completion:** 2017-12
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2016-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02544724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02544724, "NM-IL-12 (rHuIL-12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02544724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*